The germline challenge in allogeneic transplantation: from donor selection to outcomes [0.03%]
同种异体移植中的生殖细胞挑战：从供者选择到预后
Amagoia Ruiz Martin,Cristina Bilbao-Sieyro,Ruth Stuckey et al.
Amagoia Ruiz Martin et al.
Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma? [0.03%]
纠正：在大B细胞淋巴瘤高危患者中使用改良的淋巴耗竭预处理方案能否提高特西 geneclcel治疗效果？
Marta Canelo-Vilaseca,Mohamad Sabbah,Caterina Cristinelli et al.
Marta Canelo-Vilaseca et al.
Published Erratum
Bone marrow transplantation. 2026 Mar 2. DOI:10.1038/s41409-026-02809-0 2026
Real-world experience of treosulfan in allogeneic stem cell transplantation in adult patients with myeloid malignancies. Spanish Group of SCT and Cell Therapy (GETH-TC) [0.03%]
Treosulfan在成人髓系肿瘤allo SCT中的真实世界经验（西班牙SCT和细胞治疗组）
Juan Manuel Cerezo-Martín,Lucrecia Yañez,Mercedes Colorado et al.
Juan Manuel Cerezo-Martín et al.
CAR T cells and T cell engagers for autoimmunity-lessons from hematology [0.03%]
造血经验教训的自身免疫CAR-T细胞和T细胞连接剂
Sarah Kayser,Arnon Nagler
Sarah Kayser
Autoimmune diseases are driven by dysregulated immune responses against self-antigens, resulting in chronic inflammation and progressive tissue damage. Chimeric antigen receptor (CAR) T cell therapy and T cell engagers, initially developed ...
Donor-derived del[20q] following allogeneic-hematopoietic cell transplantation: a case with 26-year follow-up and literature review [0.03%]
供者来源del（20q）异基因造血细胞移植后病例报告及文献回顾
Clara Bouley,Min Fang,Jerald Radich et al.
Clara Bouley et al.
Donor-derived cytogenetic abnormalities are a rare finding following allogeneic hematopoietic cell transplantation. Deletion of the long arm of chromosome 20 [del(20q)] is one of the more frequently observed structural abnormalities, but it...
CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis [0.03%]
急性淋巴细胞白血病患者使用CAR-T细胞疗法的系统评价和meta分析
Victor Navarro,Gloria Iacoboni,Sergi Camarillas et al.
Victor Navarro et al.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL), with high remission rates across various CAR T-cell constructs. Ho...
Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy [0.03%]
CAR-T细胞输注时的疾病状态与复发/难治大B细胞淋巴瘤的真实世界结局：桥接治疗无关的预后意义
Yu Yagi,Yusuke Kanemasa,Hideki Goto et al.
Yu Yagi et al.
PTCy versus ATG in HLA-matched sibling donor allogeneic transplantation: Comment on: Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party [0.03%]
PLT 回输与 ATG 在 HLA 配型相合的同胞供者异基因移植中对移植物抗宿主病和复发率的影响：EBMT 登记处研究及其移植物并发症工作组的评论文章
Nihar Desai,Auro Viswabandya
Nihar Desai
Microbiome, GvHD, and immune reconstitution in allogeneic hematopoietic cell transplantation [0.03%]
异基因造血细胞移植中的微生物组、GVHD和免疫重建
Daniela Weber,Misbah Tariq,Mette Hazenberg et al.
Daniela Weber et al.
The gut microbiota has emerged as a critical factor influencing outcomes following allogeneic hematopoietic cell transplantation (alloHCT). Notably, disruptions to the intestinal microbiome-referred to as dysbiosis-have been strongly linked...
Treatment outcome and efficacy of desensitization strategies for immunized-PTR in hematological malignancies before hematopoietic stem cell transplantation [0.03%]
免疫后血细胞输注患者的脱敏治疗效果及预后研究
Yizhou Pan,Yuanling Zuo,Qingya Cui et al.
Yizhou Pan et al.
Immunized platelet transfusion refractoriness (immunized-PTR) correlates with poor outcomes in hematological malignancies (HM) patients during allogeneic hematopoietic stem-cell transplantation (allo-HSCT). The efficacy and outcomes of dese...